General
Celecoxib and Sulindac Drugs Reduce Recurring Colon Cancer Risk - Medical News Bulletin
 

Celecoxib and Sulindac Drugs Reduce Recurring Colon Cancer Risk - Medical News Bulletin

Shared by:

 
A 2016 systematic review investigated the safety and efficacy of various substances in the prevention of recurring colon cancer. It was found that the non-steroidal anti-inflammatory drugs celecoxib and sulindac reduce recurring colon cancer risk significantly, though are associated with a moderately increased risk of serious adverse events.
 
www.medicalnewsbulletin.com
 
11 Jan 2017 - General